BLOOD, LYMPH AND RELATED CONDITIONS:@0.084848:0.038601:0.564720:0.038601:0.564720:0.019343:0.084848:0.019343:0.013500:0.010866:0.020438:0.020438:0.017498:0.006515:0.006515:0.008735:0.013923:0.021613:0.013923:0.016063:0.006515:0.017404:0.017404:0.017498:0.006515:0.014276:0.012606:0.010866:0.015466:0.010019:0.012606:0.017498:0.006515:0.019121:0.020438:0.017404:0.017498:0.005315:0.010019:0.005315:0.020438:0.017404:0.011712
96:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
are options. Clinical trials should be con-:@0.084242:0.096166:0.475173:0.096166:0.475173:0.080410:0.084242:0.080410:0.013143:0.005715:0.012508:0.007991:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007991:0.015644:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.008005:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.008005:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.008005:0.013123:0.012508:0.007995:0.012450:0.012604:0.011738:0.006388
sidered in all patients where available, as :@0.084242:0.112530:0.480457:0.112530:0.480457:0.096774:0.084242:0.096774:0.007466:0.003848:0.013181:0.012508:0.005719:0.012508:0.013181:0.006581:0.003848:0.011738:0.006581:0.013143:0.003848:0.003848:0.006594:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006581:0.015990:0.011738:0.012508:0.005709:0.012508:0.006581:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.005330:0.006602:0.013143:0.007466:0.005330
there are no curative options as yet, apart :@0.084242:0.128895:0.480490:0.128895:0.480490:0.113139:0.084242:0.113139:0.006523:0.011738:0.012508:0.005705:0.012508:0.004955:0.013143:0.005715:0.012508:0.004955:0.011738:0.012604:0.004949:0.012450:0.011699:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.004965:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.004953:0.013143:0.007466:0.004965:0.010314:0.012508:0.006523:0.005330:0.004951:0.013143:0.013123:0.013143:0.005792:0.006523:0.005330
from  stem-cell transplantation.  Despite :@0.084242:0.145259:0.480478:0.145259:0.480478:0.129503:0.084242:0.129503:0.006042:0.005711:0.012604:0.018049:0.005330:0.010799:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.016144:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.010791:0.014316:0.012508:0.007466:0.013123:0.003848:0.006523:0.012508:0.005330
recent advances in stem-cell transplanta-:@0.084242:0.161624:0.475158:0.161624:0.475158:0.145868:0.084242:0.145868:0.005713:0.012508:0.012450:0.012508:0.011738:0.006523:0.005848:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.007466:0.005869:0.003848:0.011738:0.005859:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005869:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006388
tion, this remains an option for a minority :@0.084242:0.177988:0.480480:0.177988:0.480480:0.162232:0.084242:0.162232:0.006523:0.003848:0.012604:0.011738:0.005330:0.007601:0.006523:0.011738:0.003848:0.007466:0.007601:0.005713:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.007601:0.013143:0.011738:0.007601:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007601:0.006042:0.012604:0.005792:0.007601:0.013143:0.007601:0.018049:0.003848:0.011738:0.012604:0.005792:0.003848:0.006523:0.010314:0.005330
of patients, due to the frequent presence :@0.084242:0.194352:0.480519:0.194352:0.480519:0.178597:0.084242:0.178597:0.012604:0.006042:0.006158:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.006158:0.013181:0.011699:0.012508:0.006158:0.006523:0.012604:0.006158:0.006523:0.011738:0.012508:0.006158:0.006042:0.005713:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.006158:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330
of multiple  comorbidities, the scarcity of :@0.084242:0.210862:0.480486:0.210862:0.480486:0.195107:0.084242:0.195107:0.012604:0.006042:0.009275:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.003945:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.009275:0.006523:0.011738:0.012508:0.009275:0.007466:0.012450:0.013143:0.005661:0.012450:0.003848:0.006523:0.010314:0.009275:0.012604:0.006042:0.005330
matched donors and limitations in perfor-:@0.084242:0.227372:0.475163:0.227372:0.475163:0.211617:0.084242:0.211617:0.018049:0.013143:0.006523:0.012450:0.011738:0.012508:0.013181:0.006335:0.013181:0.012604:0.011738:0.012604:0.005792:0.007466:0.006327:0.013143:0.011738:0.013181:0.006340:0.003848:0.003848:0.018049:0.003848:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.006350:0.003848:0.011738:0.006340:0.013123:0.012508:0.006708:0.006042:0.012604:0.005792:0.006388
mance status.:@0.084242:0.243882:0.215610:0.243882:0.215610:0.228127:0.084242:0.228127:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.005330
5:@0.215604:0.238255:0.221819:0.238255:0.221819:0.229069:0.215604:0.229069:0.006215
All patients require  supportive care, :@0.102424:0.260384:0.480507:0.260384:0.480507:0.244628:0.102424:0.244628:0.014239:0.003848:0.003848:0.016087:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.016087:0.005711:0.012508:0.013123:0.011699:0.003848:0.005719:0.012508:0.005330:0.010745:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.003848:0.010660:0.012508:0.016087:0.012450:0.013143:0.005715:0.012508:0.005330:0.005330
which may include psychosocial support, :@0.084240:0.276894:0.480472:0.276894:0.480472:0.261138:0.084240:0.261138:0.015990:0.011738:0.003848:0.012450:0.011738:0.006908:0.018049:0.013143:0.010314:0.006908:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006908:0.013123:0.007466:0.010314:0.012450:0.011738:0.012604:0.007466:0.012604:0.012450:0.003848:0.013143:0.003848:0.006920:0.007466:0.011699:0.013123:0.013123:0.012604:0.005792:0.006523:0.005330:0.005330
clinical  and haematological monitoring :@0.084240:0.293404:0.480495:0.293404:0.480495:0.277648:0.084240:0.277648:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330:0.007212:0.013143:0.011738:0.013181:0.012527:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.012527:0.018049:0.012604:0.011738:0.003848:0.006523:0.012604:0.005792:0.003848:0.011738:0.012950:0.005330
for  disease deterioration  or  progression, :@0.084240:0.309914:0.480476:0.309914:0.480476:0.294158:0.084240:0.294158:0.006042:0.012604:0.005792:0.005330:0.006238:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.011584:0.013181:0.012508:0.006523:0.012508:0.005792:0.003848:0.012604:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006231:0.012604:0.005792:0.005330:0.006240:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.005330
quality-of-life assessment, transfusion, iron :@0.084240:0.326424:0.480491:0.326424:0.480491:0.310668:0.084240:0.310668:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.006388:0.012604:0.006042:0.006388:0.003848:0.003848:0.006042:0.012508:0.007939:0.013143:0.007466:0.007466:0.012508:0.007466:0.007466:0.018049:0.012508:0.011738:0.006523:0.005330:0.007928:0.006523:0.005792:0.013143:0.011738:0.007466:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.005330:0.007928:0.003848:0.005715:0.012604:0.011738:0.005330
chelation therapy (in transfusional iron :@0.084240:0.342934:0.480470:0.342934:0.480470:0.327178:0.084240:0.327178:0.012450:0.011738:0.012508:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.014432:0.006523:0.011738:0.012508:0.005780:0.013143:0.013123:0.010314:0.014432:0.007100:0.003848:0.011738:0.014432:0.006523:0.005792:0.013143:0.011738:0.007466:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.014432:0.003848:0.005717:0.012604:0.011738:0.005330
overload),  antibiotics for  infections  and :@0.084240:0.359444:0.480476:0.359444:0.480476:0.343688:0.084240:0.343688:0.012604:0.010660:0.012508:0.005792:0.003848:0.012604:0.013143:0.013181:0.007100:0.005330:0.005330:0.006608:0.013143:0.011738:0.006523:0.003848:0.013123:0.003848:0.012604:0.006523:0.003848:0.012450:0.007466:0.011950:0.006042:0.012604:0.005792:0.005330:0.006602:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006606:0.013143:0.011738:0.013181:0.005330
cytokines (e.g., erythropoietin, G-CSF, :@0.084240:0.375954:0.480505:0.375954:0.480505:0.360198:0.084240:0.360198:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.007466:0.019954:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.019954:0.012508:0.005792:0.010314:0.006523:0.011738:0.005703:0.012604:0.013123:0.012604:0.003848:0.012508:0.006523:0.003848:0.011738:0.005330:0.019954:0.016779:0.006388:0.015644:0.009583:0.006983:0.005330:0.005330
etc.). Thrombopoietin-receptor  agonists :@0.084240:0.392464:0.480499:0.392464:0.480499:0.376708:0.084240:0.376708:0.012508:0.006523:0.012450:0.005330:0.007100:0.005330:0.016067:0.008197:0.011738:0.005711:0.012604:0.018049:0.013123:0.012604:0.013123:0.012604:0.003848:0.012508:0.006523:0.003848:0.011738:0.006388:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005330:0.010726:0.013143:0.012950:0.012604:0.011738:0.003848:0.007466:0.006523:0.007466:0.005330
and similar agents are under active inves-:@0.084240:0.408974:0.475155:0.408974:0.475155:0.393218:0.084240:0.393218:0.013143:0.011738:0.013181:0.005753:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005753:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005753:0.013143:0.005715:0.012508:0.005753:0.011699:0.011738:0.013181:0.012508:0.005792:0.005740:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.005753:0.003848:0.011738:0.010660:0.012508:0.007466:0.006388
tigation for the management of clinically :@0.084240:0.425484:0.480466:0.425484:0.480466:0.409728:0.084240:0.409728:0.006523:0.003848:0.012950:0.013143:0.006523:0.003848:0.012604:0.011738:0.007237:0.006042:0.012604:0.005792:0.007233:0.006523:0.011738:0.012508:0.007243:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.007231:0.012604:0.006042:0.007237:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330
significant  thrombocytopaenia.  Iron  che-:@0.084240:0.441994:0.475157:0.441994:0.475157:0.426238:0.084240:0.426238:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.003100:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330:0.003096:0.004349:0.005715:0.012604:0.011738:0.005330:0.003094:0.012450:0.011738:0.012508:0.006388
lators (e.g., deferasirox, deferoxamine) :@0.084240:0.458504:0.480493:0.458504:0.480493:0.442748:0.084240:0.442748:0.003848:0.013143:0.006523:0.012604:0.005792:0.007466:0.015817:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.015817:0.013181:0.012508:0.006042:0.012508:0.005792:0.013143:0.007466:0.003848:0.005715:0.012604:0.009236:0.005330:0.015817:0.013181:0.012508:0.006042:0.012508:0.005709:0.012604:0.009236:0.013143:0.018049:0.003848:0.011738:0.012508:0.007100:0.005330
have been shown in non-randomised, but :@0.084240:0.475014:0.480487:0.475014:0.480487:0.459258:0.084240:0.459258:0.011738:0.013143:0.010660:0.012508:0.005446:0.013123:0.012508:0.012508:0.011738:0.005446:0.007466:0.011738:0.012604:0.015990:0.011738:0.005446:0.003848:0.011738:0.005446:0.011738:0.012604:0.011738:0.006388:0.005792:0.013143:0.011738:0.013170:0.012604:0.018049:0.003848:0.007466:0.012508:0.013181:0.005330:0.005446:0.013123:0.011699:0.006523:0.005330
prospective trials to improve survival and :@0.084240:0.491524:0.480478:0.491524:0.480478:0.475768:0.084240:0.475768:0.013123:0.005715:0.012604:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007793:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.007793:0.006523:0.012604:0.007780:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.007782:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.007793:0.013143:0.011738:0.013181:0.005330
improve  cell  counts  in  a  significant  per-:@0.084240:0.508034:0.475148:0.508034:0.475148:0.492278:0.084240:0.492278:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.005330:0.004610:0.012450:0.012508:0.003848:0.003848:0.005330:0.004616:0.012450:0.012604:0.011699:0.011738:0.006523:0.007466:0.005330:0.004605:0.003848:0.011738:0.005330:0.004612:0.013143:0.005330:0.004614:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.004607:0.013123:0.012508:0.005792:0.006388
centage of patients.:@0.084240:0.524544:0.275567:0.524544:0.275567:0.508788:0.084240:0.508788:0.012450:0.012508:0.011738:0.006523:0.013143:0.012950:0.012508:0.005330:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
13,14:@0.275548:0.518925:0.303516:0.518925:0.303516:0.509740:0.275548:0.509740:0.006215:0.006215:0.003107:0.006215:0.006215
SPECIALIST REFERRAL:@0.084242:0.558211:0.314253:0.558211:0.314253:0.538614:0.084242:0.538614:0.012230:0.013170:0.012230:0.018344:0.006585:0.017404:0.010348:0.006585:0.012230:0.009878:0.006585:0.013641:0.012230:0.011289:0.012230:0.013641:0.013641:0.017404:0.010348
Although  very few patients with MDS will :@0.084242:0.577014:0.480449:0.577014:0.480449:0.561258:0.084242:0.561258:0.014239:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330:0.002931:0.010660:0.012508:0.005792:0.010314:0.008274:0.006042:0.012508:0.015990:0.008274:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008274:0.015990:0.003848:0.006523:0.011738:0.008274:0.017684:0.014316:0.009583:0.008274:0.015990:0.003848:0.003848:0.003848:0.005330
be cured, many of the above-mentioned :@0.084242:0.593524:0.480497:0.593524:0.480497:0.577768:0.084242:0.577768:0.013123:0.012508:0.006129:0.012450:0.011699:0.005709:0.012508:0.013181:0.005330:0.006127:0.018049:0.013143:0.011738:0.010314:0.006138:0.012604:0.006042:0.006123:0.006523:0.011738:0.012508:0.006119:0.013143:0.013123:0.012604:0.010660:0.012508:0.006388:0.018049:0.012508:0.011738:0.006523:0.003848:0.012604:0.011738:0.012508:0.013181:0.005330
treatments may result in improved quality :@0.084242:0.610034:0.480488:0.610034:0.480488:0.594278:0.084242:0.594278:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007466:0.006629:0.018049:0.013143:0.010314:0.006639:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.006639:0.003848:0.011738:0.006639:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.006639:0.013123:0.011699:0.013143:0.003848:0.003848:0.006523:0.010314:0.005330
of life, decreased transfusions, a reduction :@0.084242:0.626544:0.480476:0.626544:0.480476:0.610788:0.084242:0.610788:0.012604:0.006042:0.004753:0.003848:0.003848:0.006042:0.012508:0.005330:0.004753:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.004753:0.006523:0.005792:0.013143:0.011738:0.007466:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.007466:0.005330:0.004753:0.013143:0.004753:0.005713:0.012508:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
in complications, decreased progression :@0.084242:0.643054:0.480470:0.643054:0.480470:0.627298:0.084242:0.627298:0.003848:0.011738:0.009968:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.009968:0.013181:0.012508:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.009968:0.013123:0.005717:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
to AML and increased overall survival. As :@0.084242:0.659564:0.480492:0.659564:0.480492:0.643808:0.084242:0.643808:0.006523:0.012604:0.007293:0.014239:0.017684:0.008890:0.007291:0.013143:0.011738:0.013181:0.007299:0.003848:0.011738:0.012450:0.005711:0.012508:0.013143:0.007466:0.012508:0.013181:0.007302:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.007312:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.007312:0.014239:0.007466:0.005330
the diagnostic and therapeutic aspects :@0.084242:0.676074:0.480472:0.676074:0.480472:0.660318:0.084242:0.660318:0.006523:0.011738:0.012508:0.010449:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.010449:0.013143:0.011738:0.013181:0.010449:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011690:0.006523:0.003848:0.012450:0.010449:0.013143:0.007466:0.013123:0.012508:0.012450:0.006523:0.007466:0.005330
have become very complex and increas-:@0.084242:0.692584:0.475175:0.692584:0.475175:0.676828:0.084242:0.676828:0.011738:0.013143:0.010660:0.012508:0.005850:0.013123:0.012508:0.012450:0.012604:0.018049:0.012508:0.005836:0.010660:0.012508:0.005792:0.010314:0.005850:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.005850:0.013143:0.011738:0.013181:0.005850:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.006388
ingly individualised, all patients with unex-:@0.084242:0.709094:0.475142:0.709094:0.475142:0.693338:0.084242:0.693338:0.003848:0.011738:0.012950:0.003848:0.010314:0.006292:0.003848:0.011738:0.013181:0.003848:0.010660:0.003848:0.013181:0.011699:0.013143:0.003866:0.003848:0.007466:0.012508:0.013181:0.005330:0.006292:0.013143:0.003848:0.003848:0.006304:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006292:0.015990:0.003848:0.006523:0.011738:0.006292:0.011699:0.011738:0.012508:0.009236:0.006388
plained cytopaenias and/or diagnosed :@0.084242:0.725604:0.480482:0.725604:0.480482:0.709848:0.084242:0.709848:0.013123:0.003848:0.013143:0.003848:0.011738:0.012508:0.013181:0.012392:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.007466:0.012392:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.012392:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.012508:0.013181:0.005330
MDS,  should  be  referred  to  a clinical :@0.084242:0.742114:0.480474:0.742114:0.480474:0.726358:0.084242:0.726358:0.017684:0.014316:0.009583:0.005330:0.005330:0.009073:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330:0.009071:0.013123:0.012508:0.005330:0.009071:0.005713:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.005330:0.009073:0.006523:0.012604:0.005330:0.009073:0.013143:0.014413:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330
haematologist.:@0.084242:0.758624:0.224520:0.758624:0.224520:0.742868:0.084242:0.742868:0.011738:0.013143:0.012508:0.018049:0.013143:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.005330
REFERENCES:@0.084242:0.788416:0.195079:0.788416:0.195079:0.772382:0.084242:0.772382:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084242:0.805332:0.103194:0.805332:0.103194:0.791327:0.084242:0.791327:0.009476:0.004738:0.004738
 Vardiman JW, :@0.120589:0.805332:0.237988:0.805332:0.237988:0.791327:0.120589:0.791327:0.000000:0.010230:0.011682:0.005047:0.011716:0.003421:0.016044:0.011682:0.010434:0.004817:0.008244:0.014605:0.004738:0.004738
et al:@0.238062:0.805332:0.274891:0.805332:0.274891:0.791327:0.238062:0.791327:0.011118:0.005798:0.004810:0.011682:0.003421
. The 2008 revision of the :@0.274891:0.805332:0.479892:0.805332:0.479892:0.791327:0.274891:0.791327:0.004738:0.004810:0.007286:0.010434:0.011118:0.004806:0.009476:0.009476:0.009476:0.009476:0.004823:0.005078:0.011118:0.009476:0.003421:0.006636:0.003421:0.011203:0.010434:0.004823:0.011203:0.005371:0.004810:0.005798:0.010434:0.011118:0.004738
World Health Organization  (WHO) classi-:@0.120589:0.819631:0.475145:0.819631:0.475145:0.805626:0.120589:0.805626:0.015635:0.011203:0.005148:0.003421:0.011716:0.010570:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.010570:0.014864:0.005162:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.005824:0.006312:0.016420:0.011682:0.014864:0.006312:0.010570:0.011067:0.003421:0.011682:0.006636:0.006636:0.003431:0.005679
fication  of  myeloid  neoplasms  and  acute :@0.120589:0.833943:0.479892:0.833943:0.479892:0.819937:0.120589:0.819937:0.004165:0.004165:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.002701:0.011203:0.005371:0.004738:0.002704:0.016044:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.004738:0.002713:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.016044:0.006636:0.004738:0.002713:0.011682:0.010434:0.011716:0.004738:0.002708:0.011682:0.011067:0.010399:0.005798:0.011118:0.004738
leukemia: rationale and important chang-:@0.120589:0.848242:0.475145:0.848242:0.475145:0.834236:0.120589:0.834236:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.006072:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.011118:0.006072:0.011682:0.010434:0.011716:0.006072:0.003421:0.016044:0.011665:0.011203:0.005148:0.005798:0.011682:0.010434:0.005798:0.006072:0.011067:0.010434:0.011682:0.010434:0.011511:0.005679
es. :@0.120589:0.862541:0.147819:0.862541:0.147819:0.848536:0.120589:0.848536:0.011118:0.006636:0.004738:0.004738
Blood. :@0.147819:0.862541:0.204657:0.862541:0.204657:0.848536:0.147819:0.848536:0.009818:0.003421:0.011203:0.011203:0.011716:0.004738:0.004738
2009;114:937-951.:@0.204657:0.862541:0.347735:0.862541:0.347735:0.848536:0.204657:0.848536:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
2. :@0.523636:0.094732:0.542588:0.094732:0.542588:0.080727:0.523636:0.080727:0.009476:0.004738:0.004738
  Verburgh, :@0.559983:0.094732:0.645164:0.094732:0.645164:0.080727:0.559983:0.080727:0.004738:-0.004738:0.010281:0.011118:0.005148:0.011665:0.010399:0.005148:0.011511:0.010434:0.004738:0.004738
et al. :@0.648755:0.094732:0.698580:0.094732:0.698580:0.080727:0.648755:0.080727:0.011118:0.005798:0.008330:0.011682:0.003421:0.004738:0.004738
A new disease  categori-:@0.702172:0.094732:0.914539:0.094732:0.914539:0.080727:0.702172:0.080727:0.012657:0.008330:0.010434:0.011118:0.014214:0.008330:0.011716:0.003421:0.006636:0.011118:0.011682:0.006636:0.011118:0.004738:0.003604:0.011067:0.011682:0.005798:0.011118:0.011511:0.011203:0.005148:0.003409:0.005679
zation of low-grade myelodysplastic syn-:@0.559983:0.109125:0.914534:0.109125:0.914534:0.095120:0.559983:0.095120:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.009596:0.011203:0.005371:0.009596:0.003421:0.011203:0.014214:0.005679:0.011511:0.005148:0.011682:0.011716:0.011118:0.009596:0.016044:0.009168:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.011665:0.003433:0.011682:0.006636:0.005798:0.003421:0.011067:0.009596:0.006636:0.009168:0.010434:0.005679
dromes based on the expression of cytope-:@0.559983:0.123519:0.914560:0.123519:0.914560:0.109513:0.559983:0.109513:0.011716:0.005078:0.011203:0.016044:0.011118:0.006636:0.003866:0.011665:0.011682:0.006636:0.011118:0.011716:0.003866:0.011203:0.010434:0.003866:0.005798:0.010434:0.011118:0.003857:0.011118:0.008210:0.011665:0.005077:0.011118:0.006636:0.006636:0.003421:0.011203:0.010434:0.003866:0.011203:0.005371:0.003866:0.011067:0.009168:0.005798:0.011203:0.011665:0.011118:0.005679
nia and dysplasia in one versus more than :@0.559983:0.137900:0.919264:0.137900:0.919264:0.123895:0.559983:0.123895:0.010434:0.003421:0.011682:0.005901:0.011682:0.010434:0.011716:0.005901:0.011716:0.009168:0.006636:0.011665:0.003421:0.011682:0.006636:0.003421:0.011682:0.005928:0.003421:0.010434:0.005901:0.011203:0.010434:0.011118:0.005901:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.005901:0.016044:0.011203:0.005073:0.011118:0.005901:0.005798:0.010434:0.011682:0.010434:0.004738
one  lineage  improves  on  the  WHO classi-:@0.559983:0.152294:0.914539:0.152294:0.914539:0.138288:0.559983:0.138288:0.011203:0.010434:0.011118:0.004738:0.002581:0.003421:0.003421:0.010434:0.011118:0.011682:0.011511:0.011118:0.004738:0.002590:0.003421:0.016044:0.011665:0.005083:0.011203:0.009476:0.011118:0.006636:0.004738:0.002590:0.011203:0.010434:0.004738:0.002583:0.005798:0.010434:0.011118:0.004738:0.002583:0.016420:0.011682:0.014864:0.007338:0.011067:0.003421:0.011682:0.006636:0.006636:0.003423:0.005679
fication. :@0.559983:0.166675:0.631394:0.166675:0.631394:0.152670:0.559983:0.152670:0.004165:0.004165:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738
Leukemia:@0.635704:0.166675:0.715975:0.166675:0.715975:0.152670:0.635704:0.152670:0.007902:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682
.  2007 Apr;21(4):668-77. :@0.715975:0.166675:0.919264:0.166675:0.919264:0.152670:0.715975:0.152670:0.004738:0.004738:0.004314:0.009476:0.009476:0.009476:0.009476:0.009065:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738
Epub 2007 Feb 15.:@0.559983:0.181068:0.709766:0.181068:0.709766:0.167063:0.559983:0.167063:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.004738
3. :@0.523636:0.195462:0.542588:0.195462:0.542588:0.181457:0.523636:0.181457:0.009476:0.004738:0.004738
  Louw,  VJ. Myelodysplastic syndromes. :@0.559983:0.195462:0.919288:0.195462:0.919288:0.181457:0.559983:0.181457:0.004738:-0.004738:0.007902:0.011203:0.010399:0.014214:0.004738:0.004738:0.014085:0.012007:0.008244:0.004738:0.018832:0.015719:0.009168:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011084:0.018832:0.006636:0.009168:0.010434:0.011716:0.005082:0.011203:0.016044:0.011118:0.006636:0.004738:0.004738
Tropical Hemato-Oncology:@0.559983:0.209855:0.786633:0.209855:0.786633:0.195850:0.559983:0.195850:0.007286:0.005148:0.011203:0.011665:0.003421:0.011067:0.011682:0.003421:0.005679:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.005679:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 1st ed. Charn: :@0.786633:0.209855:0.919306:0.209855:0.919306:0.195850:0.786633:0.195850:0.004738:0.005670:0.009476:0.006636:0.005798:0.005679:0.011118:0.011716:0.004738:0.005670:0.013906:0.010434:0.011682:0.005502:0.010434:0.004738:0.004738
Springer International AG; 2015: 269-277.:@0.559983:0.224237:0.892901:0.224237:0.892901:0.210231:0.559983:0.210231:0.008518:0.011665:0.005148:0.003421:0.010434:0.011511:0.011118:0.005148:0.004738:0.003866:0.010434:0.005798:0.011118:0.005489:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.012657:0.014915:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
4. :@0.523636:0.238336:0.542588:0.238336:0.542588:0.224331:0.523636:0.224331:0.009476:0.004738:0.004738
  Wong  TN,:@0.559983:0.238336:0.640943:0.238336:0.640943:0.224331:0.559983:0.224331:0.004738:-0.004738:0.015635:0.011203:0.010434:0.011511:0.004738:0.002757:0.007286:0.012657:0.004738
 et al. :@0.640938:0.238336:0.697451:0.238336:0.697451:0.224331:0.640938:0.224331:0.007509:0.011118:0.005798:0.007509:0.011682:0.003421:0.004738:0.004738
Role of  TP53 mutations  in :@0.700222:0.238336:0.919311:0.238336:0.919311:0.224331:0.700222:0.224331:0.010382:0.011203:0.003421:0.011118:0.007509:0.011203:0.005371:0.004738:0.002762:0.007286:0.010126:0.009476:0.009476:0.007509:0.016044:0.010399:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.002762:0.003421:0.010434:0.004738
the origin and evolution of therapy-related :@0.559983:0.252424:0.919299:0.252424:0.919299:0.238418:0.559983:0.238418:0.005798:0.010434:0.011118:0.004912:0.011203:0.005148:0.003421:0.011511:0.003421:0.010434:0.004918:0.011682:0.010434:0.011716:0.004926:0.011118:0.009476:0.011203:0.003421:0.010399:0.005798:0.003421:0.011203:0.010434:0.004912:0.011203:0.005371:0.004914:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.005082:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.004738
acute myeloid  leukaemia. :@0.559983:0.266523:0.796461:0.266523:0.796461:0.252518:0.559983:0.252518:0.011682:0.011067:0.010399:0.005798:0.011118:0.011682:0.016044:0.009168:0.011118:0.003421:0.011203:0.003421:0.011716:0.004738:0.006955:0.003421:0.011118:0.010399:0.008586:0.011682:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Nature:@0.803405:0.266523:0.860209:0.266523:0.860209:0.252518:0.803405:0.252518:0.012657:0.011682:0.005798:0.010399:0.005148:0.011118
. 2015 :@0.860209:0.266523:0.919270:0.266523:0.919270:0.252518:0.860209:0.252518:0.004738:0.011682:0.009476:0.009476:0.009476:0.009476:0.004738
Feb;518(7540):552-5. Epub 2014 Dec 08.:@0.559983:0.280622:0.886163:0.280622:0.886163:0.266617:0.559983:0.266617:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738:0.004738:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.004738
5. :@0.523636:0.294710:0.542588:0.294710:0.542588:0.280705:0.523636:0.280705:0.009479:0.004734:0.004738
  Louw VJ, :@0.559983:0.294710:0.638063:0.294710:0.638063:0.280705:0.559983:0.280705:0.004738:-0.004738:0.007560:0.010861:0.010057:0.013872:0.007028:0.011665:0.007902:0.004396:0.004738
et al. :@0.640339:0.294710:0.687154:0.294710:0.687154:0.280705:0.640339:0.280705:0.010776:0.005456:0.007030:0.011340:0.003079:0.004396:0.004738
Guideline for the treatment :@0.689446:0.294710:0.919308:0.294710:0.919308:0.280705:0.689446:0.280705:0.014573:0.010057:0.003079:0.011374:0.010776:0.003079:0.003079:0.010092:0.010776:0.007030:0.005029:0.010861:0.004806:0.007030:0.005456:0.010092:0.010776:0.007030:0.005456:0.004736:0.010776:0.011340:0.005456:0.015702:0.010776:0.010092:0.005797:0.004738
of myelodysplastic syndromes (MDS) in South :@0.559983:0.308809:0.919264:0.308809:0.919264:0.294804:0.559983:0.294804:0.010861:0.005029:0.004127:0.015702:0.008826:0.010776:0.003079:0.010861:0.011374:0.008826:0.006294:0.011323:0.003079:0.011340:0.006294:0.005456:0.003079:0.010724:0.004127:0.006294:0.008826:0.010092:0.011374:0.004734:0.010861:0.015702:0.010776:0.006294:0.004127:0.005969:0.015377:0.012384:0.008176:0.005969:0.004127:0.003079:0.010092:0.004127:0.008176:0.010861:0.010057:0.005456:0.010432:0.004738
Africa. :@0.559983:0.322897:0.616410:0.322897:0.616410:0.308892:0.559983:0.308892:0.012315:0.005029:0.004806:0.003079:0.010724:0.011340:0.004396:0.004738
S Afr Med J.:@0.616051:0.322897:0.709732:0.322897:0.709732:0.308892:0.616051:0.308892:0.008176:0.004396:0.012315:0.005029:0.004806:0.004396:0.015377:0.010776:0.011374:0.004396:0.007902:0.004738
 2011;101(12):900-906.:@0.709390:0.322897:0.881596:0.322897:0.881596:0.308892:0.709390:0.308892:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.005969:0.009134:0.009134:0.005969:0.004396:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.004738
6. :@0.523636:0.336996:0.542588:0.336996:0.542588:0.322991:0.523636:0.322991:0.009476:0.004738:0.004738
  Ma X, :@0.559983:0.336996:0.612386:0.336996:0.612386:0.322991:0.559983:0.322991:0.004738:-0.004738:0.015719:0.011682:0.005109:0.010417:0.004738:0.004738
et al:@0.612750:0.336996:0.649873:0.336996:0.649873:0.322991:0.612750:0.322991:0.011118:0.005798:0.005104:0.011682:0.003421
. Myelodysplastic syndromes: In-:@0.649873:0.336996:0.914548:0.336996:0.914548:0.322991:0.649873:0.322991:0.004738:0.005106:0.015719:0.009168:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011085:0.005114:0.006636:0.009168:0.010434:0.011716:0.005082:0.011203:0.016044:0.011118:0.006636:0.004738:0.005104:0.003866:0.010434:0.005679
cidence and survival in the United States. :@0.559983:0.351096:0.919291:0.351096:0.919291:0.337090:0.559983:0.337090:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.006996:0.011682:0.010434:0.011716:0.006996:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.006996:0.003421:0.010434:0.006996:0.005798:0.010434:0.011118:0.006985:0.011203:0.010434:0.003421:0.005798:0.011118:0.011716:0.006985:0.008518:0.005798:0.011682:0.005798:0.011118:0.006636:0.004738:0.004738
Cancer:@0.559983:0.365183:0.623338:0.365183:0.623338:0.351178:0.559983:0.351178:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. 2007;109:1536-42.:@0.623338:0.365183:0.775891:0.365183:0.775891:0.351178:0.623338:0.351178:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7. :@0.523636:0.379283:0.542588:0.379283:0.542588:0.365277:0.523636:0.365277:0.009476:0.004738:0.004738
  Sant  M, :@0.559983:0.379283:0.630479:0.379283:0.630479:0.365277:0.559983:0.365277:0.004738:-0.004738:0.008518:0.011682:0.010434:0.005798:0.004738:0.004131:0.015719:0.004738:0.004738
et  al:@0.634609:0.379283:0.675496:0.379283:0.675496:0.365277:0.634609:0.365277:0.011118:0.005798:0.004738:0.004129:0.011682:0.003421
.  Incidence  of  hematologic :@0.675496:0.379283:0.919288:0.379283:0.919288:0.365277:0.675496:0.365277:0.004738:0.004738:0.004129:0.003866:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004738:0.004129:0.011203:0.005371:0.004738:0.004129:0.010434:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738
malignancies in Europe by morphologic :@0.559983:0.393382:0.919294:0.393382:0.919294:0.379377:0.559983:0.379377:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.003421:0.011118:0.006636:0.011015:0.003421:0.010434:0.011015:0.009168:0.010399:0.005080:0.011203:0.011665:0.011118:0.011015:0.011665:0.009168:0.011015:0.016044:0.011203:0.005148:0.011665:0.010434:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738
subtype: results of the HAEMACARE pro-:@0.559983:0.407469:0.914555:0.407469:0.914555:0.393464:0.559983:0.393464:0.006636:0.010399:0.011665:0.005798:0.009168:0.011665:0.011118:0.004738:0.009749:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.009749:0.011203:0.005371:0.009749:0.005798:0.010434:0.011118:0.009749:0.011682:0.012657:0.009168:0.015719:0.012657:0.013906:0.012657:0.010382:0.009168:0.009749:0.011665:0.005080:0.011203:0.005679
ject. :@0.559983:0.421569:0.600914:0.421569:0.600914:0.407564:0.559983:0.407564:0.003472:0.011118:0.011067:0.005798:0.004738:0.004738
Blood:@0.600914:0.421569:0.648276:0.421569:0.648276:0.407564:0.600914:0.407564:0.009818:0.003421:0.011203:0.011203:0.011716
. 2010;116(19):3724.:@0.648276:0.421569:0.807774:0.421569:0.807774:0.407564:0.648276:0.407564:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
8. :@0.523636:0.435656:0.542588:0.435656:0.542588:0.421651:0.523636:0.421651:0.009476:0.004738:0.004738
  Smith  A, :@0.559983:0.435656:0.638290:0.435656:0.638290:0.421651:0.559983:0.421651:0.004738:-0.004738:0.008518:0.016044:0.003421:0.005798:0.010434:0.004738:0.007221:0.012657:0.004738:0.004738
et al:@0.645505:0.435656:0.689480:0.435656:0.689480:0.421651:0.645505:0.421651:0.011118:0.005798:0.011956:0.011682:0.003421
. Incidence of haemato-:@0.689480:0.435656:0.914539:0.435656:0.914539:0.421651:0.689480:0.421651:0.004738:0.011956:0.003866:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.011956:0.011203:0.005371:0.011956:0.010434:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.005679
logical malignancy  by sub-type:  a  report :@0.559983:0.449756:0.919301:0.449756:0.919301:0.435750:0.559983:0.435750:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.008125:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.009168:0.004738:0.003378:0.011665:0.009168:0.008125:0.006636:0.010399:0.011665:0.005679:0.005798:0.009168:0.011665:0.011118:0.004738:0.004738:0.003378:0.011682:0.004738:0.003378:0.005078:0.011118:0.011665:0.011203:0.005148:0.005798:0.004738
from the Haematological Malignancy Re-:@0.559983:0.463855:0.914553:0.463855:0.914553:0.449850:0.559983:0.449850:0.005371:0.005077:0.011203:0.016044:0.007218:0.005798:0.010434:0.011118:0.007218:0.011682:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.007218:0.015719:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.009168:0.007218:0.010382:0.011118:0.005679
search Network. :@0.559983:0.477943:0.699060:0.477943:0.699060:0.463937:0.559983:0.463937:0.006636:0.011118:0.011682:0.005030:0.011067:0.010434:0.004909:0.012657:0.011118:0.005798:0.014214:0.011203:0.005148:0.008586:0.004738:0.004738
Br J Cancer:@0.699213:0.477943:0.795596:0.477943:0.795596:0.463937:0.699213:0.463937:0.009818:0.005148:0.004909:0.008244:0.004909:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. 2011 Nov;105 :@0.795596:0.477943:0.919305:0.477943:0.919305:0.463937:0.795596:0.463937:0.004738:0.004909:0.009476:0.009476:0.009486:0.009476:0.004909:0.012657:0.011203:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
(11):1684-92. Epub 2011 Nov 01.:@0.559983:0.492042:0.820346:0.492042:0.820346:0.478037:0.559983:0.478037:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011203:0.009476:0.004738:0.009476:0.009476:0.004738
9. :@0.523636:0.506141:0.542588:0.506141:0.542588:0.492136:0.523636:0.492136:0.009476:0.004738:0.004738
  Ryblom  H, :@0.559983:0.506141:0.651337:0.506141:0.651337:0.492136:0.559983:0.492136:0.004738:-0.004738:0.010933:0.009168:0.011665:0.003421:0.011203:0.016044:0.004738:0.003024:0.011682:0.004738:0.004738
et  al. :@0.654365:0.506141:0.703615:0.506141:0.703615:0.492136:0.654365:0.492136:0.011118:0.005798:0.004738:0.003017:0.011682:0.003421:0.004738:0.004738
Self-perception  of  symp-:@0.706643:0.506141:0.914546:0.506141:0.914546:0.492136:0.706643:0.492136:0.008518:0.011118:0.003421:0.005371:0.005679:0.011665:0.011118:0.005032:0.011067:0.011118:0.011665:0.005798:0.003421:0.011203:0.010434:0.004738:0.003015:0.011203:0.005371:0.004738:0.003019:0.006636:0.009168:0.016044:0.011665:0.005679
toms of anemia and fatigue before and :@0.559983:0.520229:0.919289:0.520229:0.919289:0.506224:0.559983:0.506224:0.005798:0.011203:0.016044:0.006636:0.008569:0.011203:0.005371:0.008569:0.011682:0.010434:0.011118:0.016044:0.003421:0.011682:0.008569:0.011682:0.010434:0.011716:0.008569:0.005371:0.011682:0.005798:0.003421:0.011511:0.010399:0.011118:0.008569:0.011665:0.011118:0.005371:0.011203:0.005075:0.011118:0.008569:0.011682:0.010434:0.011716:0.004738
after blood transfusions in patients with my-:@0.559983:0.534328:0.914563:0.534328:0.914563:0.520323:0.559983:0.520323:0.011682:0.005371:0.005798:0.011118:0.005148:0.004539:0.011665:0.003421:0.011203:0.011203:0.011716:0.004550:0.005798:0.005148:0.011682:0.010434:0.006636:0.005371:0.010399:0.006636:0.003421:0.011203:0.010434:0.006636:0.004550:0.003421:0.010434:0.004550:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004550:0.014214:0.003421:0.005798:0.010434:0.004550:0.016044:0.009168:0.005679
elodysplastic syndromes. :@0.559983:0.548428:0.770724:0.548428:0.770724:0.534422:0.559983:0.534422:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.006277:0.006636:0.009168:0.010434:0.011716:0.005078:0.011203:0.016044:0.011118:0.006636:0.004738:0.004738
Eur J Oncol Nurs.:@0.772246:0.548428:0.914555:0.548428:0.914555:0.534422:0.772246:0.534422:0.009168:0.010399:0.005148:0.006260:0.008244:0.006260:0.014864:0.010434:0.011067:0.011203:0.003421:0.006260:0.012657:0.010399:0.005148:0.006636:0.004738
 :@0.914539:0.548428:0.919277:0.548428:0.919277:0.534422:0.914539:0.534422:0.004738
2015;19(2):99-106.:@0.559983:0.562515:0.706208:0.562515:0.706208:0.548510:0.559983:0.548510:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.   Swerdlow SH, Campo E, Harris NL, :@0.523636:0.576615:0.863652:0.576615:0.863652:0.562609:0.523636:0.562609:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.014214:0.011118:0.005044:0.011716:0.003421:0.011203:0.014214:0.009425:0.008518:0.011682:0.004738:0.009425:0.013906:0.011682:0.016044:0.011665:0.011203:0.009425:0.009168:0.004738:0.009425:0.011682:0.011682:0.005148:0.005148:0.003421:0.006636:0.009425:0.012657:0.007902:0.004738:0.004738
et al:@0.868339:0.576615:0.909783:0.576615:0.909783:0.562609:0.868339:0.562609:0.011118:0.005798:0.009425:0.011682:0.003421
. :@0.909783:0.576615:0.919258:0.576615:0.919258:0.562609:0.909783:0.562609:0.004738:0.004738
World Health Organization classification of :@0.559983:0.590714:0.919291:0.590714:0.919291:0.576709:0.559983:0.576709:0.016420:0.011203:0.005148:0.003421:0.011716:0.006067:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.006072:0.014864:0.005148:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.006067:0.011067:0.003421:0.011682:0.006636:0.006636:0.003421:0.004165:0.004177:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006067:0.011203:0.005371:0.004738
tumours of haematopoietic and lymphoid :@0.559983:0.604802:0.919277:0.604802:0.919277:0.590796:0.559983:0.590796:0.005798:0.010399:0.016044:0.011203:0.010399:0.005148:0.006636:0.006448:0.011203:0.005371:0.006448:0.010434:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.011665:0.011203:0.003421:0.011118:0.005798:0.003421:0.011067:0.006448:0.011682:0.010434:0.011716:0.006448:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.003421:0.011716:0.004738
tissues:@0.559983:0.618901:0.610629:0.618901:0.610629:0.604896:0.559983:0.604896:0.005798:0.003421:0.006636:0.006636:0.010399:0.011118:0.006636
. Volume 2. Lyon: IARC Press; 2008.:@0.610629:0.618901:0.891279:0.618901:0.891279:0.604896:0.610629:0.604896:0.004738:0.004738:0.010276:0.011203:0.003421:0.010399:0.016044:0.011118:0.004738:0.009476:0.004738:0.004738:0.007500:0.009168:0.011203:0.010434:0.004738:0.004738:0.003866:0.012657:0.010382:0.013906:0.004738:0.010126:0.005059:0.011118:0.006636:0.006636:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Giagounidis A, :@0.523636:0.632989:0.687026:0.632989:0.687026:0.618983:0.523636:0.618983:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.014915:0.003421:0.011682:0.011511:0.011203:0.010399:0.010434:0.003421:0.011716:0.003421:0.006636:0.006149:0.012657:0.004738:0.004738
et al. :@0.688420:0.632989:0.736055:0.632989:0.736055:0.618983:0.688420:0.618983:0.011118:0.005798:0.006140:0.011682:0.003421:0.004738:0.004738
Morphology, cytoge-:@0.737458:0.632989:0.914539:0.632989:0.914539:0.618983:0.737458:0.618983:0.015719:0.011203:0.005148:0.011665:0.010434:0.011191:0.003421:0.011203:0.011511:0.009168:0.004738:0.006140:0.011067:0.009168:0.005798:0.011203:0.011511:0.011113:0.005679
netics and classification of MDS. :@0.559983:0.647088:0.831433:0.647088:0.831433:0.633083:0.559983:0.633083:0.010434:0.011118:0.005798:0.003421:0.011067:0.006636:0.005331:0.011682:0.010434:0.011716:0.005333:0.011067:0.003421:0.011682:0.006636:0.006636:0.003421:0.004165:0.004177:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.005328:0.011203:0.005371:0.005328:0.015719:0.012726:0.008518:0.004738:0.004738
Best Pract :@0.832028:0.647088:0.919294:0.647088:0.919294:0.633083:0.832028:0.633083:0.009818:0.011118:0.006636:0.005798:0.005337:0.010126:0.005148:0.011682:0.011067:0.005798:0.004738
Res Clin Haematol:@0.559983:0.661187:0.711408:0.661187:0.711408:0.647182:0.559983:0.647182:0.010382:0.011118:0.006636:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.011682:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421
. 2013;26:337-53.:@0.711408:0.661187:0.845010:0.661187:0.845010:0.647182:0.711408:0.647182:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
12.   Greenberg PL, :@0.523636:0.675581:0.686533:0.675581:0.686533:0.661575:0.523636:0.661575:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.014915:0.005078:0.011118:0.011118:0.010434:0.011665:0.011118:0.005148:0.011511:0.006941:0.010126:0.007902:0.004738:0.004738
et al:@0.688745:0.675581:0.727708:0.675581:0.727708:0.661575:0.688745:0.661575:0.011118:0.005798:0.006944:0.011682:0.003421
. Revised international :@0.727708:0.675581:0.919294:0.675581:0.919294:0.661575:0.727708:0.661575:0.004738:0.006944:0.010382:0.011118:0.009476:0.003421:0.006636:0.011118:0.011716:0.006944:0.003421:0.010434:0.005798:0.011118:0.005508:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738
prognostic scoring system for myelodysplas-:@0.560000:0.689962:0.914556:0.689962:0.914556:0.675957:0.560000:0.675957:0.011665:0.005080:0.011203:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.003101:0.006636:0.011067:0.011203:0.005148:0.003421:0.010434:0.011511:0.003113:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.003113:0.005371:0.011203:0.005148:0.003103:0.016044:0.009168:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.011665:0.003421:0.011682:0.006642:0.005679
tic syndromes. :@0.560000:0.704355:0.690914:0.704355:0.690914:0.690350:0.560000:0.690350:0.005798:0.003421:0.011067:0.013119:0.006636:0.009168:0.010434:0.011716:0.005077:0.011203:0.016044:0.011118:0.006636:0.004738:0.004738
Blood:@0.699281:0.704355:0.746643:0.704355:0.746643:0.690350:0.699281:0.690350:0.009818:0.003421:0.011203:0.011203:0.011716
. 2012;120(12):2454. :@0.746643:0.704355:0.919282:0.704355:0.919282:0.690350:0.746643:0.690350:0.004738:0.013119:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009498:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
Epub 2012 Jun 27.:@0.560000:0.718737:0.707782:0.718737:0.707782:0.704732:0.560000:0.704732:0.009168:0.011665:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.010399:0.010434:0.004738:0.009476:0.009476:0.004738
13.   Angelucci  E,:@0.523653:0.733130:0.666367:0.733130:0.666367:0.719125:0.523653:0.719125:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.012657:0.010434:0.011511:0.011118:0.003421:0.010399:0.011067:0.011067:0.003421:0.004738:0.002629:0.009168:0.004738
 et al:@0.666367:0.733130:0.713130:0.733130:0.713130:0.719125:0.666367:0.719125:0.007372:0.011118:0.005798:0.007372:0.011682:0.003421
. Deferasirox for transfu-:@0.713130:0.733130:0.914568:0.733130:0.914568:0.719125:0.713130:0.719125:0.004738:0.007372:0.012726:0.011118:0.005371:0.011118:0.005148:0.011682:0.006636:0.003421:0.005080:0.011203:0.008210:0.007372:0.005371:0.011203:0.005148:0.007372:0.005798:0.005148:0.011682:0.010434:0.006636:0.005371:0.010399:0.005679
sion-dependent  patients with myelodys-:@0.560000:0.747524:0.914563:0.747524:0.914563:0.733518:0.560000:0.733518:0.006636:0.003421:0.011203:0.010434:0.005679:0.011716:0.011118:0.011665:0.011118:0.010434:0.011716:0.011118:0.010434:0.005798:0.004738:0.007755:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.012503:0.014214:0.003421:0.005798:0.010434:0.012503:0.016044:0.009168:0.011118:0.003421:0.011203:0.011716:0.009168:0.006636:0.005679
plastic  syndromes:  safety,  efficacy,  and :@0.560000:0.761905:0.919306:0.761905:0.919306:0.747900:0.560000:0.747900:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.004738:0.007076:0.006636:0.009168:0.010434:0.011716:0.005078:0.011203:0.016044:0.011118:0.006636:0.004738:0.004738:0.007064:0.006636:0.011682:0.005371:0.011118:0.005798:0.009168:0.004738:0.004738:0.007066:0.011118:0.005371:0.004165:0.004165:0.011067:0.011682:0.011067:0.009168:0.004738:0.004738:0.007064:0.011682:0.010434:0.011716:0.004738
beyond (GIMEMA MDS0306  Trial). :@0.560000:0.776299:0.861718:0.776299:0.861718:0.762293:0.560000:0.762293:0.011665:0.011118:0.009168:0.011203:0.010434:0.011716:0.012315:0.006312:0.014915:0.003866:0.015719:0.009168:0.015719:0.012657:0.012315:0.015719:0.012726:0.008518:0.009476:0.009476:0.009476:0.009476:0.004738:0.007591:0.006773:0.005148:0.003421:0.011682:0.003421:0.006312:0.004738:0.004738
Eur J :@0.869295:0.776299:0.919308:0.776299:0.919308:0.762293:0.869295:0.762293:0.009168:0.010399:0.005148:0.012315:0.008244:0.004738
Haematol:@0.560000:0.790692:0.642631:0.790692:0.642631:0.776687:0.560000:0.776687:0.011682:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421
. 2014;92:527-36.:@0.642631:0.790692:0.776233:0.790692:0.776233:0.776687:0.642631:0.776687:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
14.   Rose  C,  e:@0.523653:0.805074:0.648402:0.805074:0.648402:0.791068:0.523653:0.791068:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010382:0.011203:0.006636:0.011118:0.004738:0.004912:0.013906:0.004738:0.004738:0.004912:0.011118
t  al:@0.648402:0.805074:0.678954:0.805074:0.678954:0.791068:0.648402:0.791068:0.005798:0.004738:0.004912:0.011682:0.003421
.  Prospective  evaluation  of :@0.678954:0.805074:0.919301:0.805074:0.919301:0.791068:0.678954:0.791068:0.004738:0.004738:0.004912:0.010126:0.005073:0.011203:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.004918:0.011118:0.009476:0.011682:0.003421:0.010399:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004918:0.011203:0.005371:0.004738
the  effect of  deferasirox  on  hematologic :@0.560000:0.819467:0.919317:0.819467:0.919317:0.805462:0.560000:0.805462:0.005798:0.010434:0.011118:0.004738:0.003565:0.011118:0.005417:0.005371:0.011118:0.011067:0.005798:0.008313:0.011203:0.005371:0.004738:0.003565:0.011716:0.011118:0.005371:0.011118:0.005148:0.011682:0.006636:0.003421:0.005080:0.011203:0.008210:0.004738:0.003566:0.011203:0.010434:0.004738:0.003563:0.010434:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004738
response in transfusion-dependent patients :@0.560000:0.833848:0.919298:0.833848:0.919298:0.819843:0.560000:0.819843:0.005078:0.011118:0.006636:0.011665:0.011203:0.010434:0.006636:0.011118:0.004105:0.003421:0.010434:0.004105:0.005798:0.005148:0.011682:0.010434:0.006636:0.005371:0.010399:0.006636:0.003421:0.011203:0.010434:0.005679:0.011716:0.011118:0.011665:0.011118:0.010434:0.011716:0.011118:0.010434:0.005798:0.004093:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738
with low-risk MDS and iron  overload:  The :@0.560000:0.848242:0.919325:0.848242:0.919325:0.834236:0.560000:0.834236:0.014214:0.003421:0.005798:0.010434:0.008826:0.003421:0.011203:0.014214:0.005679:0.005148:0.003421:0.006636:0.008586:0.008826:0.015719:0.012726:0.008518:0.008826:0.011682:0.010434:0.011716:0.008826:0.003421:0.005082:0.011203:0.010434:0.004738:0.004076:0.011203:0.009476:0.011118:0.005148:0.003421:0.011203:0.011682:0.011716:0.004738:0.004738:0.004078:0.007286:0.010434:0.011118:0.004738
Rythmex Study. :@0.560000:0.862623:0.691519:0.862623:0.691519:0.848618:0.560000:0.848618:0.010933:0.009168:0.005798:0.010434:0.016044:0.011118:0.008210:0.004738:0.008518:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Blood:@0.691498:0.862623:0.738860:0.862623:0.738860:0.848618:0.691498:0.848618:0.009818:0.003421:0.011203:0.011203:0.011716
. 2016;128:2008.:@0.738860:0.862623:0.866784:0.862623:0.866784:0.848618:0.738860:0.848618:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738